Type 2 diabetes
Conditions
Interventions
Basal insulin plus SGLT-2 inhibitor(52 weeks)
Basal insulin plus GLP-1 receptor agonist (52 weeks)
Basal insulin plus rapid insulin (52 weeks)
Sponsors
Tokyo Women's Medical University Hospital
NS building Clinic Tomonaga Clinic
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Participants with type 2 diabetes 2. Participants who can perform self-monitoring blood glucose 3. BMI<=45 kg/m2 4. HbA1c between 7.0 to 10.5 %
Exclusion criteria
Exclusion criteria: 1.Participants with severe liver dysfunction 2.Participants with severe renal dysfunction 3.Participants with severe diabetic complications 4.Participants who are pregnant, hope to be pregnant, or are in lactation period 5.Participants whose fasting serum C-peptide immunoreactivity below 0.5ng/ml 6.Participants whose postprandial serum C-peptide immunoreactivity below 0.5ng/ml
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Change in HbA1c after 52 weeks Change in weight after 52 weeks | — |
Secondary
| Measure | Time frame |
|---|---|
| Level of self-monitoring of blood glucose Frequency of hypoglycemia Change in amount of insulin | — |
Countries
Japan
Contacts
Public ContactJunko Oya
Tokyo Women's Medical University Hospital Diabetes center
Outcome results
None listed